Tesamorelin (Egrifta SV)
Egrifta SV · TH9507
A stabilized GHRF analog that stimulates pituitary GH release; approval is indication-specific.
Mechanism
Growth hormone–releasing factor analog
Protocol studied in research
Study design shown in plain language. This is not a personal dosing recommendation.
Adults with HIV and excess abdominal fat
Community-Reported Research Schedules
Descriptive community patterns are separated from clearly labeled trial-derived reference rows. Neither is personal dosing guidance.
| Research context or phase | Amount per administration | Schedule total | Frequency | Timing | Administration | Evidence level |
|---|---|---|---|---|---|---|
| Common daily schedule | 1–2 mg | 1–2 mg/day | Once daily | Consistent daily time | Subcutaneous | Community-reported |
Important: Repetition in online communities does not establish product identity, safety, effectiveness, or an appropriate exposure. Route-specific schedules, half-life estimates and reported cycle lengths are shown for comparison only.
Example Reconstitution Protocol
A hypothetical concentration calculation for literacy and review—not preparation, administration, or dosing instructions.
Approved tesamorelin presentations have product-specific vial strengths, supplied diluent and preparation instructions; use the exact label rather than generic math.
Important: Vial strength, diluent identity, compatibility, sterility, stability and beyond-use time are product-specific. Never infer them from this arithmetic example. Use manufacturer, pharmacy, study, or licensed-clinician instructions for an actual preparation.
Community-Reported Preparation Notes
Diluent reports, visible-change signals, and formulation sensitivity—kept separate from validated product instructions.
Bacteriostatic water is the most frequently described community choice.
Sterile water and acidified laboratory solvents are also discussed, but reports are not interchangeable across formulations.
- Community consistency
- Mixed
- Cloudiness / gel signal
- Higher-priority watch
Concentration, pH, temperature, vial formulation, and agitation.
Product-specific instructions take priority. Reports about generic or compounded vials do not validate a universal diluent.
Visible-change discard rule: Do not use or attempt to salvage material with persistent cloudiness, strings, flakes, precipitate, unusual thickening, or gel formation.
Cycle & Supplies Planning
Phase-by-phase cycle math showing how long a vial lasts and the estimated supplies required.
Cycle Structure
| Phase | Amount | Frequency | Weekly total |
|---|---|---|---|
| Weeks 1–2 | 1 mg per administration | 5 times weekly | 5 mg/week |
| Week 3 onward | 2 mg per administration | 5 times weekly | 10 mg/week |
Peptide Vials
| Cycle | Total compound | Vials needed | How long one vial lasts |
|---|---|---|---|
| 8 weeks | 70 mg | 7 × 10 mg | 2 weeks initially; 1 week after escalation |
| 12 weeks | 110 mg | 11 × 10 mg | 2 weeks initially; 1 week after escalation |
Bacteriostatic Water
| Cycle | Total water used | 10 mL bottles needed |
|---|---|---|
| 8 weeks | 14 mL | 2 × 10 mL |
| 12 weeks | 22 mL | 3 × 10 mL |
Insulin Syringes (U-100)
| Cycle | Administrations | Syringes needed |
|---|---|---|
| 8 weeks | 40 | 40 |
| 12 weeks | 60 | 60 |
The seven-vial 8-week total assumes five administrations per week. Counts are rounded up; water-bottle totals assume 10 mL bottles.
Planning boundary: These are arithmetic examples based on the displayed research schedule—not personal dosing or purchasing instructions. Confirm product format, compatibility, route, sterility, storage, and discard timing independently. U-100 units measure liquid volume, not potency.
Safety signal
Labeling includes warnings for malignancy, elevated IGF-1, fluid retention, glucose intolerance and hypersensitivity.
Reported doses describe either a specific study or an unverified community pattern. Neither is personal medical guidance.